Skip to main content
SpringerLink
Log in

Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

We evaluated the clinical features and the prognostic factors of hepatocellular carcinoma (HCC) developed after hepatitis C virus (HCV) eradication with interferon (IFN) therapy.

Methods

Forty-one consecutive patients who developed HCC after HCV eradication with IFN therapy were enrolled. Clinical features were reviewed, and overall survival and associated factors were analyzed. The recurrence rate in 26 patients receiving radical therapy was also analyzed.

Results

Twenty patients developed HCC within 5 years after the end of IFN therapy, 9 patients developed the disease from 5 to 10 years after the end of the therapy, 9 patients developed the disease from 10 to 15 years after the end of the therapy, and 3 patients developed the disease from 15 years after the end of the therapy. Multivariate analysis of independent variables for the development of HCC within 5 years identified age >55 years at HCV eradication (P = 0.007) and heavy alcohol intake (P = 0.009). The 5-year survival rate was 64%. On multivariate analysis of overall survival for the 41 patients, the only risk factor with prognostic influence was radical therapy (P = 0.010), which was associated with a cumulative 5-year survival rate of 91%. The only independent factor for the receipt of radical therapy was regular surveillance for HCC (P = 0.004). Among patients receiving radical therapy, the 3- and 5-year recurrence rates were 18 and 18%, respectively.

Conclusion

We found that, despite HCV eradication, patients with the risk factors of high age at HCV eradication and heavy alcohol intake might be at heightened risk for the development of HCC within 5 years after HCV eradication. In contrast, risk factors for the development of HCC more than 10 years after HCV eradication were uncertain. These findings indicate the need for long-term surveillance for HCC after HCV eradication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–801.

    Article  PubMed  CAS  Google Scholar 

  2. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995;21:650–5.

    Article  PubMed  CAS  Google Scholar 

  3. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology. 1995;22:1027–33.

    Article  PubMed  CAS  Google Scholar 

  4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.

    Article  PubMed  Google Scholar 

  5. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47–53.

    Article  PubMed  CAS  Google Scholar 

  6. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–72.

    Article  PubMed  CAS  Google Scholar 

  7. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 1990;12:680–7.

    Article  PubMed  CAS  Google Scholar 

  8. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Bisceglie AD, Peters M, et al. Treatment of chronic hepatitis non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med. 1986;315:1575–8.

    Article  PubMed  CAS  Google Scholar 

  9. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998;27:1394–402.

    Article  PubMed  CAS  Google Scholar 

  10. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 1998;129:94–9.

    PubMed  CAS  Google Scholar 

  11. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124–30.

    Article  PubMed  CAS  Google Scholar 

  12. Poynard T, Moussalli J, Ratziu V, Regimbeau C, Opolon P. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis. 1999;3:869–81.

    Article  PubMed  CAS  Google Scholar 

  13. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174–81.

    PubMed  CAS  Google Scholar 

  14. Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut. 2004;53:425–30.

    Article  PubMed  CAS  Google Scholar 

  15. Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol. 2004;99:636–44.

    Article  PubMed  CAS  Google Scholar 

  16. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma on chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol. 1999;30:653–9.

    Article  PubMed  CAS  Google Scholar 

  17. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer. 2000;87:741–9.

    Article  PubMed  CAS  Google Scholar 

  18. Kim SR, Matsuoka T, Maekawa Y, Yano Y, Imoto S, Kudo M, et al. Development of multicentric hepatocellular carcinoma after completion of interferon therapy. J Gastroenterol. 2002;37:663–8.

    Article  PubMed  Google Scholar 

  19. Shindo M, Hamada K, Oda Y, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology. 2001;33:1299–302.

    Article  PubMed  CAS  Google Scholar 

  20. Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005;40:148–56.

    Article  PubMed  CAS  Google Scholar 

  21. Toyoda H, Kumada T, Tokuda A, Sano K, Kubota K, Makuuchi M. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. J Viral Hepat. 2000;7:414–9.

    Article  PubMed  CAS  Google Scholar 

  22. Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616–22.

    Article  PubMed  CAS  Google Scholar 

  23. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002;123:483–91.

    Article  PubMed  CAS  Google Scholar 

  24. Enokimura N, Shiraki K, Kawakita T, Saitou Y, Inoue H, Okano H, et al. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res. 2003;23:593–6.

    PubMed  Google Scholar 

  25. Mashitani T, Yoshiji H, Yamazaki M, Ikenaka Y, Noguchi R, Ishikawa M, et al. Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report. Cases J. 2009;2(1):18.

    PubMed  Google Scholar 

  26. Miki D, Aikata H, Uka K, Saneto H, Kawaoka T, Azakami T, et al. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol. 2008;43(7):550–7.

    Article  PubMed  Google Scholar 

  27. Saneto H, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, et al. Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients. J Gastroenterol. 2008;43(12):975–81.

    Article  PubMed  CAS  Google Scholar 

  28. Chiba T, Matsuzaki Y, Abei M, Shoda J, Aikawa T, Tanaka N, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol. 1996;31:552–8.

    Article  PubMed  CAS  Google Scholar 

  29. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131–6.

    Article  PubMed  CAS  Google Scholar 

  30. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer. 2000;89(1):53–9.

    Google Scholar 

  31. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105–14.

    PubMed  CAS  Google Scholar 

  32. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88:1472–7.

    Article  PubMed  CAS  Google Scholar 

  33. Braga C, La Vecchia C, Negri E, Franceschi S. Attributable risks for hepatocellular carcinoma in Northern Italy. Eur J Cancer. 1997;83:1820–6.

    Google Scholar 

  34. La Vecchia C, Negri E, Decali A, Franceschi S. Diabetes mellitus and the risk of primary liver cancer. Int J Cancer. 1997;73:204–7.

    Article  PubMed  CAS  Google Scholar 

  35. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36:1206–13.

    Article  PubMed  CAS  Google Scholar 

  36. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460–8.

    Article  PubMed  Google Scholar 

  37. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127:S17–26.

    Article  PubMed  Google Scholar 

  38. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.

    Article  PubMed  Google Scholar 

  39. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.

    Article  PubMed  Google Scholar 

  40. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM, et al. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127:S97–103.

    Article  PubMed  CAS  Google Scholar 

  41. Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6:459–64.

    Article  PubMed  Google Scholar 

  42. Waranabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol. 2008;43:509–18.

    Article  Google Scholar 

  43. Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, Tsurumaru M, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer. 1993;71:19–25.

    Article  PubMed  CAS  Google Scholar 

  44. Grazi GL, Ercoloani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001;234:71–8.

    Article  PubMed  CAS  Google Scholar 

  45. Lise M, Bacchetti S, Pian PD, Nitti D, Pilati PL, Pigato P. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. Cancer. 1998;82:1028–36.

    Article  PubMed  CAS  Google Scholar 

  46. Izumi R, Shimizu K, Il T, Yagi M, Matsui O, Nonomura A, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 1994;106:720–7.

    PubMed  CAS  Google Scholar 

  47. Ercolani G, Grazi GL, Ravaioli M, Gaudio MD, Gardini A, Cescon M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237:536–43.

    PubMed  Google Scholar 

  48. Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Ko Shimada K, Hiraguri M, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000;191:381–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Programs for Biomedical Research, Division of Frontier Medical Science, Department of Medicine and Molecular Science, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan

    Yuko Nagaoki, Hiroshi Aikata, Daisuke Miyaki, Eisuke Murakami, Yoshimasa Hashimoto, Yoshio Katamura, Takahiro Azakami, Tomokazu Kawaoka, Shintaro Takaki, Akira Hiramatsu, Koji Waki, Michio Imamura, Yoshiiku Kawakami, Shoichi Takahashi & Kazuaki Chayama

Authors
  1. Yuko Nagaoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Aikata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daisuke Miyaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eisuke Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshimasa Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshio Katamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takahiro Azakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomokazu Kawaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shintaro Takaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akira Hiramatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Koji Waki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Michio Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yoshiiku Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shoichi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kazuaki Chayama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Aikata.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagaoki, Y., Aikata, H., Miyaki, D. et al. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol 46, 799–808 (2011). https://doi.org/10.1007/s00535-011-0384-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-011-0384-z

Keywords

Search

Navigation